About EBSA14 Conference - Estoril

EBSA14 Conference - Estoril


09.00 Opening
EBSA President 2010-2011
M. Kuster, Novartis International AG, Basel/CH
09.30 An overview of biosafety in Portugal
M.S. Núncio, Portuguese National Institute of Health Dr. Ricardo Jorge, Lisbon/P
Session 1
Evolving biosafety and biosecurity frameworks: Biosecurity
10.00 Dutch preparedness and resilience to biological incidents
S. Banus, R. Bleijs, C. de Hoog, P. Sijnesael, National Institut for Public Health and the Environment, Bithoven/NL
10.30 Coffee break
11.00 The Dutch Biosecurity Regime, a users perspective
G. van Willigen, F. van Dam, Leiden University Medical Center/NL
11.30 Danish Biosecurity Regulation - a users perspective
V. Halkjaer-Knudsen, Statens Serum Institut, Copenhagen/DK
12.00 Lunch at the Centro de Congressos do Estoril
Session 2
Break-out discussions groups


Esmeralda Prat, Bayer CropScience, Gent/B
Toon De Kesel, Bayer CropScience, Gent/B

Come join us to share your views and experiences on these two topics. We all learn from each other and can influence the biosafety profession and its impact on biosafety. We will also learn what some countries are doing in terms of biosafety professional competence and certification.

Implementation of the laboratory biorisk management standard CWA 15793
- Have you implemented CWA 15793 on laboratory biorisk management?
- What is your experience?
- What is the added value of its implementation?
- Will the guidance document (WS 55) help in its implementation?

Biosafety professional competence and certification:
- Do you think it is important to set up different levels of biosafety professionals? If yes, under what criteria?
- Do the competences defined in CEN WS 53 present a benefit to you?
- What is your opinion on training modalities and duration of training?
- Is biosafety professional certification important to you? What are the benefits to you?

The subjects will be briefly introduced by a panel:
- Laboratory biorisk management system CWA 15793, its guidance document (CEN WS 55) and experiences in its implementation - Ingegerd Kallings and Juergen Mertsching
- Biosafety professional competence and certification:
- CEN WS 53 Biosafety professional competence, IFBA and ABSA certification initiatives - Esmeralda Prat
- UK initiatives - Anton de Paiva
- Swiss initiative - Ursula Jenal
- Dutch and German practices - Gijsbert van Willigen and Juergen Mertsching,


Jillian Deans, University College London/UK
Patrick Seechurn, University of Manchester/UK

Engineering controls are at the heart of controlling exposure to biological agents in the laboratory environment but how much importance is attached to ensuring that the rationale for the controls is explained and making sure that they are used correctly - eg do users know how much impact the movement of people can have on the airflows of a Class 2 microbiological safety cabinet? This session will also look at whether a more holistic approach is needed to ensure that other risks such as ill-health arising from work-place upper limb disorders are also taken into account when training staff in the use of engineering controls. Please come and share information about current practice in your institution and help identify those areas where we may need to do more - contributions from those who have experience of design of equipment and/or laboratories would be particularly welcome.


Vibeke Halkjær-Knudsen, Statens Serum Institute Copenhagen/DK
Per Staugaard, Biosafety Training & Consultancy, Utrecht/NL

Throughout Europe the effects of resolution 1540 is beginning to show, biosecurity has become an important part of the present agenda and discussions prevail in all institutions and facilities that store and/or use biological agents. Each and everyone of the member states will have to decide how they will be implementing Resolution 1540. Some countries - like Denmark have chosen to go the full mile and provide very prescriptive guidelines for both agents, spray systems and related materials, in some ways even more prescriptive than the Select Agent rules; while others, like Holland is taking a different approach and is relying on the institutions to develop their own modus of ethics and level of compliance. This break-out session will provide a forum for discussing pros and cons for these two strategies - and a forum for sharing what other initiatives that are arising throughout the regions.


Sofia Núncio, Portuguese National Institute of Health Dr. Ricardo Jorge, Lisbon/P
Philippe Stroot, Xibios Bisafety Consulting, Tournai/B

National or regional biosafety regulations and, even more, effective means to control their application may vary significantly. Authorities of countries or regions with strong regulations generally provide standards and/or guidance that help organisations to specify their containment measures and develop their biosafety management programmes. Thorough authorisation and inspection schemes also help building up a know-how that generally reveals useful for both the administration and the users. In contrast, organisations of other countries may be left without significant support. How should these institutions deal optimally with the design and construction of their facilities and the management of their programmes, knowing that they might be confronted to more stringent requirements and controls in the future? What approaches could they use concretely? And what can be done in these countries to improve the overall situation? These are a few of the questions that will be dealt with in this break-out session.


Martin Vinnell, University of Cambridge/UK

Keeping, housing and using research animals is technically and managerially challenging at the best of times. The containment of infectious agents can be similarly challenging. Working with infected animals may therefore seem like a challenge that should be avoided at all costs! This session will look at the various implications of working with infected research animals - both those purposely infected with pathogens as part of the research, and controlling and managing accidental infections and outbreaks. Discussions will consider design, infrastructure and equipment issues, management and control measure and legal compliance.


Allan Bennett, HPA and ECDC BRICK (BioRisk Initiative for Capacity building and Knowledge base development)
Amanda Ozin-Hofsaes, European Centre for Disease Prevention and Control (ECDC), Stockholm/S

2011 is the year of biosafety communities and EBSA is active in this initiative. Many European countries are well represented within EBSA and most of those have their own national biosafety associations. However if we display EBSA membership on a map of Europe we see countries which have few EBSA members and no associations. A great deal of work has been carried out to foster biosafety communities in Central Asia, the Middle East and Africa under the auspices of threat reduction initiatives. The objective of this session is to bring together ECDC whose laboratory networks are pan-European, EBSA, representatives of successful national association and delegates from countries not represented in EBSA to discuss how we can build a more representative European Biosafety Community.

14.00 Posters and coffee break
Session 3
Evolving biosafety and biosecurity frameworks: Biosafety
15.00 European research infrastructure on highly pathogenic agents
H. Raoul, Institut national de la santé et de la recherche médicale, Lyon/F
15.30 New technologies: the GMO definition revisited(link is external)
P. Rüdelsheim, PERSEUS BVBA, Zwijnaarde/B
16.00 Biosafety and biosecurity on synthetic biology, DIY bio and biohackers(link is external)
L. Pei, M. Schmidt, International Dialogue and Conflict Management, Vienna/A; W. Wei, Institute of Botany, CAS, Beijing/PRC
16.30 Production and application of nano-bio-particles - the crossroad of nano-bio risk assessment(link is external)
U. Jenal, Jenal & Partners Biosafety Consulting, Rheinfelden/CH
17.00 AGM


Session 4
Practical issues in biosafety management
08.30 Communicating biosafety(link is external)
R. Custers, VIB, Ghent/B
09.00 Creating a behaviour based safety culture: from system to culture(link is external)
A. Pardon, IMEC, Heverlee/B
09.30 CWA 15793 "Laboratory Biorisk Management": contradiction to existing laws or a structured way to improve biosafety culture?(link is external)
R. Knorr, S. Gerstel, J. Mertsching, Hanover Medical School/D
10.00 Implementation of the Laboratory Biorisk Management Standard
CWA 15793:2008 in the EDI laboratory of the central sanitary epidemiological
station of the Ministry of Health of Ukraine(link is external)
N. Vydayko, L. Nekrasova, Central Sanitary Epidemiological Station, Ministry of Health, Kiev/UA; S. Wagener, Office of Biorisk Management, Canadian Science Centre for Human and Animal Health, Winnipeg/CDN; V. Pashynska, Science and Technology Center in Ukraine, Kiev/UA
10.30 Coffee break
Session 5
Applied biosafety
11.00 Laboratory accident leading to an infection with Staphylococcus aureus(link is external)
K. Summermatter, U. Pauli, Institute of Virology and Immunoprophylaxis, Mittelhaeusern/CH
11.30 Handling viral vectors: viral shedding by infected cells and hotspots for contaminations(link is external)
C. Bagutti, M. Alt, M. Schmidlin, State Laboratory Basel-City/CH; G. Vogel, Mabritec AG, Riehen/CH; U. Vögeli, P. Brodmann, State Laboratory Basel-City/CH
12.00 Assessment of gaseous decontamination technologies for use on spacecraft(link is external)
T. Pottage, J. Walker, A. Bennett, Health Protection Agency, Salisbury/UK; T. Rohr, European Space Agency, Noordwijk/NL; C. Fowler, M. Wilson, Science and Technology Facilities Council, Didcot/UK
12.30 Lunch at the Centro de Congressos do Estoril
Session 6
13.30 Report on break outs
Session 7
Celebrating the year of biosafety
14.00 Building global biosafety: the importance of staying ahead of the research curve(link is external)
J. Welch, Elizabeth R Griffin Research Foundation, Kingsport, TN/USA
14.15 EBSA involvement in international biosafety initiatives
T. De Kesel, Bayer CropScience, Gent/B
Session 8
Chris Collins lecture
14.30 Aerosols to all that! From Pasteur to PCR, an alternative history of biosafety
A. Bennett, Health Protection Agency, Salisbury/UK
15.30 Closing remarks President 2011-2012